California State Teachers Retirement System Buys 5,037 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California State Teachers Retirement System grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 196,362 shares of the biopharmaceutical company's stock after acquiring an additional 5,037 shares during the period. California State Teachers Retirement System owned 0.15% of Alnylam Pharmaceuticals worth $46,206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ALNY. Allworth Financial LP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 38 shares during the period. Investment Management Corp of Ontario boosted its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock valued at $1,670,000 after buying an additional 40 shares during the period. Nixon Peabody Trust Co. boosted its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock valued at $540,000 after buying an additional 43 shares during the period. Brevan Howard Capital Management LP boosted its holdings in shares of Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 44 shares during the period. Finally, IFP Advisors Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the period. 92.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ALNY. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. Finally, Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded up $11.69 on Friday, hitting $304.59. 3,116,157 shares of the stock were exchanged, compared to its average volume of 929,720. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business's fifty day moving average is $260.38 and its 200 day moving average is $255.08. Alnylam Pharmaceuticals, Inc. has a 52 week low of $147.25 and a 52 week high of $306.25. The company has a market capitalization of $39.71 billion, a PE ratio of -140.36 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.16) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.